TSTae-Hoon Shin

Tae-Hoon Shin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tae-Hoon Shin has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Byung-Chul Lee

    Translational Stem Cell Biology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States

    4 shared publications
  • Cynthia E. Dunbar

    Translational Stem Cell Biology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA

    4 shared publications
  • Hyung-Sik Kim

    Department of Oral Biochemistry, Dental and Life Science Institute, School of Dentistry, Pusan National University, Yangsan, Republic of Korea

    3 shared publications
  • Yifan Zhou

    Translational Stem Cell Biology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States

    3 shared publications
  • Anthony Cook

    BIOQUAL, Inc., Rockville, MD, United States

    2 shared publications
  • Barbara J. Flynn

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

    2 shared publications

Latest Publications

  • Open Access

    Canine and feline mesenchymal stem cells: an integrative review of direct comparative studies by species and tissue source

    by Hyung-Sik Kim, Tae-Hoon Shin

    Kim HS, et al. J Vet Sci. 2025 Nov;26:e78. https://doi.org/10.4142/jvs.25163


  • Open Access

    Ongoing production of tissue-resident macrophages from hematopoietic stem cells in healthy adult macaques

    by Andrew R. Rahmberg, Chuanfeng Wu, Taehoon Shin, So Gun Hong, Luxin Pei, Tovah E. Markowitz, Heather D. Hickman, Cynthia E. Dunbar, Jason M. Brenchley

    Macrophages orchestrate tissue immunity from the initiation and resolution of antimicrobial immune responses to the repair of damaged tissue. Murine studies demonstrate that tissue-resident macrophages are a heterogenous mixture of yolk sac–derived cells that populate the tissue before birth, and bone marrow–derived replacements recruited in adult tissues at steady-state and in increased numbers in response to tissue damage or infection. How this translates to species that are constantly under immunologic challenge, such as humans, is unknown. To understand the ontogeny and longevity of tissue-resident macrophages in nonhuman primates (NHPs), we use a model of autologous hematopoietic stem progenitor cell (HSPC) transplantation with HSPCs genetically modified to be marked with clonal barcodes, allowing for subsequent analysis of clonal ontogeny. We study the contribution of HSPCs to tissue macrophages, their clonotypic profiles relative to leukocyte subsets in the peripheral blood, and their transcriptomic and epigenetic landscapes. We find that HSPCs contribute to tissue-resident macrophage populations in all anatomic sites studied. Macrophage clonotypic profiles are dynamic and overlap significantly with the clonal hierarchy of contemporaneous peripheral blood monocytes. Epigenetic and transcriptomic landscapes of HSPC-derived macrophages are similar to tissue macrophages isolated from NHPs that did not undergo transplantation. We also use in vivo bromodeoxyuridine infusions to monitor tissue macrophage turnover in NHPs that did not undergo transplantation and find evidence for macrophage turnover at steady state. These data demonstrate that the life span of most tissue-resident macrophages is limited and can be replenished continuously from HSPCs.


  • Open Access

    Investigation of the impact of clonal hematopoiesis on severity and pathophysiology of COVID-19 in rhesus macaques

    by Tae-Hoon Shin, Yifan Zhou, Byung-Chul Lee, So Gun Hong, Shayne F. Andrew, Barbara J. Flynn, Matthew Gagne, John-Paul M. Todd, Ian N. Moore, Anthony Cook, et al.

    Clinical manifestations of COVID-19 vary widely, ranging from asymptomatic to severe respiratory failure with profound inflammation. Although risk factors for severe illness have been identified, definitive determinants remain elusive. Clonal hematopoiesis (CH), the expansion of hematopoietic stem and progenitor cells bearing acquired somatic mutations, is associated with advanced age and hyperinflammation. Given the similar age range and hyperinflammatory phenotype between frequent CH and severe COVID-19, CH could impact the risk of severe COVID-19. Human cohort studies have attempted to prove this relationship, but conclusions are conflicting. Rhesus macaques (RMs) are being utilized to test vaccines and therapeutics for COVID-19. However, RMs, even other species, have not yet been reported to develop late inflammatory COVID-19 disease. Here, RMs with either spontaneous DNMT3A or engineered TET2 CH along with similarly transplanted and conditioned controls were infected with SARS-CoV-2 and monitored until 12 days post-inoculation (dpi). Although no significant differences in clinical symptoms and blood counts were noted, an aged animal with natural DNMT3A CH died on 10 dpi. CH macaques showed evidence of sustained local inflammatory responses compared to controls. Interestingly, viral loads in respiratory tracts were higher at every timepoint in the CH group. Lung sections from euthanasia showed evidence of mild inflammation in all animals, while viral antigen was more frequently detected in the lung tissues of CH macaques even at the time of autopsy. Despite the lack of striking inflammation and serious illness, our findings suggest potential pathophysiological differences in RMs with or without CH upon SARS-CoV-2 infection.


  • Open Access

    Investigation of the Impact of Clonal Hematopoiesis on Severity and Pathophysiology of COVID-19 in Rhesus Macaques

    by Tae-Hoon Shin, Yifan Zhou, Byung-Chul Lee, So Gun Hong, Shayne F. Andrew, Barbara J. Flynn, Matthew Gagne, John-Paul M. Todd, Ian N. Moore, Anthony Cook, et al.

    Clinical manifestations of COVID-19 vary widely, ranging from asymptomatic to severe respiratory failure with profound inflammation. Although risk factors for severe illness have been identified, definitive determinants remain elusive. Clonal hematopoiesis (CH), the expansion of hematopoietic stem and progenitor cells bearing acquired somatic mutations, is associated with advanced age and hyperinflammation. Given the similar age range and hyperinflammatory phenotype between frequent CH and severe COVID-19, CH could impact the risk of severe COVID-19. Human cohort studies have attempted to prove this relationship, but conclusions are conflicting. Rhesus macaques (RMs) are being utilized to test vaccines and therapeutics for COVID-19. However, RMs, even other species, have not yet been reported to develop late inflammatory COVID-19 disease. Here, RMs with either spontaneous DNMT3A or engineered TET2 CH along with similarly transplanted and conditioned controls were infected with SARS-CoV-2 and monitored until 12 days post-inoculation (dpi). Although no significant differences in clinical symptoms and blood counts were noted, an aged animal with natural DNMT3A CH died on 10 dpi. CH macaques showed evidence of sustained local inflammatory responses compared to controls. Interestingly, viral loads in respiratory tracts were higher at every timepoint in the CH group. Lung sections from euthanasia showed evidence of mild inflammation in all animals, while viral antigen was more frequently detected in the lung tissues of CH macaques even at the time of autopsy. Despite the lack of striking inflammation and serious illness, our findings suggest potential pathophysiological differences in RMs with or without CH upon SARS-CoV-2 infection. Highlights: No evidence of association between CH and COVID-19 clinical severity in macaques. The presence of CH is associated with prolonged local inflammatory responses in COVID-19. SARS-CoV-2 persists longer in respiratory tracts of macaques with CH following infection.

  • Open Access

    A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions

    by Tae-Hoon Shin, Yifan Zhou, Shirley Chen, Stefan Cordes, Max Z. Grice, Xing Fan, Byung-Chul Lee, Aisha A. Aljanahi, So Gun Hong, Kelli L. Vaughan, et al.

    Individuals with age-related clonal hematopoiesis (CH) are at greater risk for hematologic malignancies and cardiovascular diseases. However, predictive preclinical animal models to recapitulate the spectrum of human CH are lacking. Through error-corrected sequencing of 56 human CH/myeloid malignancy genes, we identified natural CH driver mutations in aged rhesus macaques matching genes somatically mutated in human CH, with DNMT3A mutations being the most frequent. A CH model in young adult macaques was generated via autologous transplantation of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9–mediated gene-edited hematopoietic stem and progenitor cells (HSPCs), targeting the top human CH genes with loss-of-function (LOF) mutations. Long-term follow-up revealed reproducible and significant expansion of multiple HSPC clones with heterozygous TET2 LOF mutations, compared with minimal expansion of clones bearing other mutations. Although the blood counts of these CH macaques were normal, their bone marrows were hypercellular and myeloid-predominant. TET2-disrupted myeloid colony-forming units isolated from these animals showed a distinct hyperinflammatory gene expression profile compared with wild type. In addition, mature macrophages purified from the CH macaques showed elevated NLRP3 inflammasome activity and increased interleukin-1β (IL-1β) and IL-6 production. The model was used to test the impact of IL-6 blockage by tocilizumab, documenting a slowing of TET2-mutated expansion, suggesting that interruption of the IL-6 axis may remove the selective advantage of mutant HSPCs. These findings provide a model for examining the pathophysiology of CH and give insights into potential therapeutic interventions.


  • Open Access

    Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

    by Yifan Zhou, Ruba Shalhoub, Stephanie N. Rogers, Shiqin Yu, Muxin Gu, Margarete A. Fabre, Pedro M. Quiros, Tae-Hoon Shin, Arch Diangson, Wenhan Deng, et al.


  • Open Access

    Mesenchymal stem cells target microglia via galectin-1 production to rescue aged mice from olfactory dysfunction

    by Yoojin Seo, Ji-Su Ahn, Ye Young Shin, Su-Jeong Oh, Min-Hye Song, Min-Jung Kang, Jung-Min Oh, Dongjun Lee, Yun Hak Kim, Byung-Chul Lee, et al.


  • CRISPR/Cas9 PIG-A gene editing in nonhuman primate model demonstrates no intrinsic clonal expansion of PNH HSPCs

    by Tae-Hoon Shin, Eun Jung Baek, Marcus A. F. Corat, Shirley Chen, Jean-Yves Metais, Aisha A. AlJanahi, Yifan Zhou, Robert E. Donahue, Kyung-Rok Yu, Cynthia E. Dunbar


  • Open Access

    Direct cell fate conversion of human somatic stem cells into cone and rod photoreceptor-like cells by inhibition of microRNA-203

    by Soon Won Choi, Ji-Hee Shin, Jae-Jun Kim, Tae-Hoon Shin, Yoojin Seo, Hyung-Sik Kim, Kyung-Sun Kang

    Direct cell fate conversion of human somatic stem cells into cone and rod photoreceptor-like cells by inhibition of microRNA-203